Prevalence estimates of recurrent balanced cytogenetic aberrations and gene fusions in unselected patients with neoplastic disorders
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Chromosome abnormalities have been reported in more than 46,000 benign and malignant neoplastic disorders, leading to the identification of numerous recurrent abnormalities. A substantial number of recurrent balanced aberrations (RBAs), in particular, reciprocal translocations, occur with remarkable specificity in association with clinical and tumor characteristics. This information has become increasingly important both in basic cancer research, as a means to identify pathogenetically important genes, and clinically, as a diagnostic and prognostic instrument. Knowledge of the frequencies of such aberrations thus is of theoretical as well as practical value. However, it is unknown to what extent the data available in the literature reflect reality. A large proportion of the published cases, at least 40%, are biased, in the sense that they were reported because of a specific or unusual karyotypic feature. We have systematically ascertained all RBAs and present data on the frequencies of these abnormalities and their molecular genetic consequences among unselected patients, that is, those studied as part of investigations of consecutive series of individuals with a particular neoplastic disorder. The salient features of the present study are: (1) published data clearly overestimate the prevalence of individual RBAs in most tumor types as well as the proportion of patients having such aberrations. In fact, several well‐known published RBAs are not recurrent or have not even been seen among unselected patients, and in no tumor entity, except for chronic myeloid leukemia, does the frequency of unselected cytogenetically abnormal neoplasms with RBAs exceed 35%; (2) the proportions of unselected cases characterized by RBAs among those tumor entities in which at least one RBA has been identified vary considerably both within and among hematologic malignancies, malignant lymphomas, and solid tumors; and (3) the molecular consequences of a substantial proportion, ranging from 19% in hematologic malignancies to 65% in epithelial tumors, of the most common RBAs in unselected patients remain to be clarified. © 2005 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Transcription factors as targets for cancer therapy
Darnell, J. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc906 · Cited by 1,194
Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia.
Golub, T. R., Barker, G. F., Bohlander, S. K., Hiebert, S. W., Ward, D. C., Bray-Ward, P., Morgan, E., Raimondi, S. C., Rowley, J. D., & Gilliland, D. G. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.11.4917 · Cited by 704
The t(12;21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion
Romana, S., Mauchauffe, M., Le Coniat, M., Chumakov, I., Le Paslier, D., Berger, R., & Bernard, O. (1995) · Blood · doi:10.1182/blood.v85.12.3662.bloodjournal85123662 · Cited by 530
Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma
Bergsagel, P. L., Chesi, M., Nardini, E., Brents, L. A., Kirby, S. L., & Kuehl, W. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.13931 · Cited by 367
Cited by
The impact of translocations and gene fusions on cancer causation
Mitelman, F., Johansson, B., & Mertens, F. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2091 · Cited by 1,400
Self-citationRecurrent gene fusions in prostate cancer
Kumar-Sinha, C., Tomlins, S. A., & Chinnaiyan, A. M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2402 · Cited by 664
Chimeric transcript discovery by paired-end transcriptome sequencing
Maher, C. A., Palanisamy, N., Brenner, J. C., Cao, X., Kalyana-Sundaram, S., Luo, S., Khrebtukova, I., Barrette, T. R., Grasso, C., Yu, J., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904720106 · Cited by 339
Cerveira, N., Ribeiro, F. R., Peixoto, A., Costa, V., Henrique, R., Jerönimo, C., & Teixeira, M. R. (2006) · Neoplasia · doi:10.1593/neo.06427 · Cited by 258
Fusion genes and chromosome translocations in the common epithelial cancers
Edwards, P. A. (2010) · The Journal of Pathology · doi:10.1002/path.2632 · Cited by 126
Evaluating biomarkers to model cancer risk post cosmic ray exposure
Sridharan, D. M., Asaithamby, A., Blattnig, S. R., Costes, S. V., Doetsch, P. W., Dynan, W. S., Hahnfeldt, P., Hlatky, L., Kidane, Y., Kronenberg, A., et al. (2016) · Life Sciences in Space Research · doi:10.1016/j.lssr.2016.05.004 · Cited by 46
Metadata
- Authors
- Mitelman, F., Mertens, F., & Johansson, B.
- Venue
- Genes, Chromosomes and Cancer
- Publisher
- Wiley
- Published
- 2005-05-03
- Volume
- 43
- Issue
- 4
- Pages
- 350-366
- ISSN
- 1045-2257 (ISSN-L)
- 1098-2264
- OpenAlex
- W2092158132
- Cited by
- 81
- References
- 4
- FWCI
- 4.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.